Gen QA

MEMBER LOGIN

MENU menu

Close close menu

Genitourinary tract tumours

BACK TO EQA DIRECTORY

Genitourinary tract tumours

EQA INFORMATION

EQA Code
TGTT
Submission
Clinical Report
Techniques
Next Generation Sequencing (NGS), Quantitative Fluorescent PCR (QF-PCR)
Eligibility
All laboratories worldwide. 
Language
English, French, German, Italian, Polish, Portuguese, Spanish
EQA Accreditation
Currently not accredited
EQA open

18 January 2027

Testing period
6 weeks

OTHER INFORMATION

  What are participants required to do?
  • Enrolled participants will receive details by email when an EQA is open for assessment and/or samples have been dispatched.  
  • Participants are expected to access the instructions and information for the cases/samples online and to analyse them according to their laboratory/centre protocols. 
  • Participants must submit their anonymised results by the deadline using their standard laboratory report or a proforma provided by GenQA.  The submitted results are independently assessed for the accuracy of the analytical/genotyping results, clinical interpretation of the results (if appropriate) and clerical accuracy (including report layout and content). 

What can I expect as a participant?
Every participant will receive:
  • An Individual Laboratory/Centre Report (ILR/ICR) with educational advice for each distribution of this EQA.
  • The Summary report for each distribution of this EQA which contains information regarding general findings, a summary of methodologies used, common errors, number of participants and benchmarking. 
  • Access to a live Performance Certificate summarising your performance status for all EQAs in which you are enrolled.

Please note: EQA details may be subject to change prior to EQA distribution.   

PRODUCTS

Sample type: Formalin-Fixed Paraffin-Embedded (FFPE) tissue sections
Testing/analysis:
Testing of all genes for this EQA is not compulsory.  Please test and report only the genes included in your routine laboratory scope.   
Conditions/Gene target(s): Bladder cancer
Renal tumours 
  • TFE3  (fusions)
  • TFEB (fusions)
  • FGFR3 (fusions and SNVs)
We aim to include a variety of disorders / scenarios / tests within each EQA.  For this EQA you may opt out of any case if it is outside of your routine laboratory scope, by following the instructions in the EQA Distribution letter.
Number of cases: Two / Three

LOGIN TO PURCHASE

 

ASK A QUESTION

Genitourinary tract tumours

Enter your details here: